Increase in Medication Reimbursements Paid by Kela
Reimbursements for medications by Kela rose by 4% to a total of 1.98 billion euros in 2025, driven by more patients using new and expensive medications.
The patent for the most expensive diabetes drug has been revoked. Are cheaper alternatives closer to reimbursement?
A patent for dapagliflozin, a leading diabetes medication, has been revoked, potentially paving the way for cheaper generic versions to be reimbursed in Poland.
Changes to the list of reimbursed medications. We will pay more for these products
The first reimbursement list of the year features 24 new molecules, including nine for oncology and 15 for non-oncological diseases, with increased costs for some medications.